Market research
BPTH Bio Path Holdings Inc
OTCQX USD Healthcare
Latest close
As of 08 Sep 2026
Test a moving-average rule with historical data.
Market facts
- Market cap
- 15K
- P/E ratio
- Not available
- Analyst target
- 2
- Dividend yield
- Not available
- Beta
- -0.43
Profile
Instrument facts
- Exchange
- OTCQX
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- Not available
- Market cap
- 15K
- P/E ratio
- Not available
- Analyst target
- 2
- Dividend yield
- Not available
- Beta
- -0.43
About
About Bio Path Holdings Inc
Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. Its drug delivery and antisense technology is the DNAbilize, a platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification that is intended to protect the DNA from destruction by the body's enzymes when circulating in vivo, incorporated inside of a lipid bilayer having neutral charge. The company's lead drug candidate is the Prexigebersen (BP1001), which is in phase 2 clinical trial for the treatment of untreated acute myeloid leukemia (AML). It is also developing BP1001-A, which is in phase 1 clinical trial for treatment of solid tumors, including ovarian, endometrial and pancreatic cancer, as well as in preclinical trial to treat obesity and related metabolic diseases; Liposomal Bcl-2 (BP1002), which is in phase 1 clinical trial to treat refractory/relapsed lymphoma and refractory/relapsed chronic lymphocytic leukemia; and Liposomal STAT3 (BP1003), which is preclinical trial for the treatment of pancreatic cancer, non-small cell lung cancer, and AML. Bio-Path Holdings, Inc. was founded in 2007 and is based in Bellaire, Texas.
Research context
Bio Path Holdings Inc appears in PyInvesting’s US Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the BPTH discussion.
5 years, 6 months ago
Bio-Path Holdings, Inc is currently in a long term uptrend where the price is trading 22.5% above its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Bio-Path Holdings, Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has dropped by 6.7% to $-3M since the same quarter in the previous year.
Finally, its free cash flow fell by 15.5% to $-3M since the same quarter in the previous year.
Based on the above factors, Bio-Path Holdings, Inc gets an overall score of 2/5.